DE69632870D1 - Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests - Google Patents

Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests

Info

Publication number
DE69632870D1
DE69632870D1 DE69632870T DE69632870T DE69632870D1 DE 69632870 D1 DE69632870 D1 DE 69632870D1 DE 69632870 T DE69632870 T DE 69632870T DE 69632870 T DE69632870 T DE 69632870T DE 69632870 D1 DE69632870 D1 DE 69632870D1
Authority
DE
Germany
Prior art keywords
detection
metasases
melanoma
multiple marker
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632870T
Other languages
English (en)
Other versions
DE69632870T2 (de
Inventor
S Hoon
Fukashi Doi
J Conrad
Peter Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAT GENETICS INST CULVER CITY
John Wayne Cancer Institute
National Genetics Institute
Original Assignee
NAT GENETICS INST CULVER CITY
John Wayne Cancer Institute
National Genetics Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAT GENETICS INST CULVER CITY, John Wayne Cancer Institute, National Genetics Institute filed Critical NAT GENETICS INST CULVER CITY
Application granted granted Critical
Publication of DE69632870D1 publication Critical patent/DE69632870D1/de
Publication of DE69632870T2 publication Critical patent/DE69632870T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
DE69632870T 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests Expired - Lifetime DE69632870T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40630795A 1995-03-17 1995-03-17
US406307 1995-03-17
PCT/US1996/003442 WO1996029430A1 (en) 1995-03-17 1996-03-13 Detection of melanoma or breast metastases with a multiple marker assay

Publications (2)

Publication Number Publication Date
DE69632870D1 true DE69632870D1 (de) 2004-08-12
DE69632870T2 DE69632870T2 (de) 2005-07-14

Family

ID=23607400

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69632870T Expired - Lifetime DE69632870T2 (de) 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
DE69637552T Expired - Lifetime DE69637552D1 (de) 1995-03-17 1996-03-13 Nachweis von Brustmetastasen unter Verwendung eines Mehrfachmarker-Tests

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637552T Expired - Lifetime DE69637552D1 (de) 1995-03-17 1996-03-13 Nachweis von Brustmetastasen unter Verwendung eines Mehrfachmarker-Tests

Country Status (6)

Country Link
US (1) US6057105A (de)
EP (2) EP1505159B1 (de)
AT (2) ATE397097T1 (de)
AU (1) AU5310296A (de)
DE (2) DE69632870T2 (de)
WO (1) WO1996029430A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
CA2250118C (en) † 1996-03-26 2009-09-29 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
AU742753C (en) * 1997-04-11 2002-12-05 Peter Kufer Primers and methods for the detection of disseminated tumor cells
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6824995B1 (en) * 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6833021B1 (en) 1998-09-21 2004-12-21 Michael Matthew Hourn Method for treating precious metal bearing minerals
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
EP1248800A2 (de) 1999-11-30 2002-10-16 Corixa Corporation Kompositionen und methoden zur therapie und diagnose von brustkrebs
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
KR100374423B1 (ko) * 2000-04-25 2003-03-28 주식회사 아이씨엔지 다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머
US7098008B2 (en) * 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
EP1158001B1 (de) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Eine Nukleinsäure, die in menschlichen Tumorzellen aufreguliert wird, ein von dieser kodiertes Protein und ein Verfahren zur Tumordiagnose
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
ES2309892T3 (es) * 2000-07-11 2008-12-16 Kirk Hogan Procedimientos y composiciones para la determinacion del perfil genomico perioperatorio.
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US6703204B1 (en) 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
WO2002070751A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
WO2002088666A2 (en) * 2001-05-01 2002-11-07 Loma Linda University Surgery Medical Group, Inc. Method for identifying lymph nodes
CA2451074C (en) 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040091857A1 (en) * 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
AU2002327308A1 (en) * 2001-07-25 2003-02-17 Oncomedx Inc. Methods for evaluating pathologic conditions using extracellular rna
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
ATE309393T1 (de) 2001-09-06 2005-11-15 Adnagen Ag Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
WO2003028539A2 (en) * 2001-10-01 2003-04-10 The Children's Hospital Of Philadelphia Materials and methods for the diagnosis of pediatric tumors
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7473526B2 (en) 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
EP1900827A3 (de) * 2002-05-21 2008-04-16 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
ATE516365T1 (de) * 2002-05-21 2011-07-15 Sysmex Corp Nukleinsäureamplifikationsprimer zum nachweis von cytokeratinen und untersuchungsverfahren mit verwendung der primer
EP1560924A4 (de) * 2002-08-16 2006-05-31 Wayne John Cancer Inst Molekulare lymphatische kartierung von virchow-lymphknoten
DE10238046A1 (de) * 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
WO2004024957A2 (en) * 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for detection of micro-metastasis
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2003290925A1 (en) * 2002-11-14 2004-06-15 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
EP1565577B1 (de) * 2002-11-28 2007-09-19 Peter Kufer Neue real-time rt-pcr methode zur sensitiven detektierung mehrerer mage gen transkripte
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US8778606B2 (en) 2003-03-04 2014-07-15 John A. Swetledge At-home cancer test
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
US8043834B2 (en) * 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
DK1526187T3 (da) * 2003-05-01 2008-11-03 Veridex Llc Intraoperative lymfeknudeassay
JP2004350685A (ja) * 2003-05-07 2004-12-16 Tosoh Corp 微小転移の検出法
TWI340168B (en) 2003-05-07 2011-04-11 Tosoh Corp Method of detecting micrometastasis
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
US7824857B2 (en) * 2003-12-02 2010-11-02 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
US20050178726A1 (en) * 2004-02-18 2005-08-18 Robert Belly Disruption of cells and tissues
WO2005084254A2 (en) * 2004-02-27 2005-09-15 Musc Foundation For Research Development Enhanced detection of rna using a panel of truncated gene-specific primers for reverse transcription
EP2290074B1 (de) 2004-05-28 2014-12-17 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
EP1774025A4 (de) 2004-07-09 2009-09-16 Univ Pittsburgh Identifizierung von markern bei lungen- und brustkrebs
JP2008523784A (ja) * 2004-09-14 2008-07-10 ジョン ウェイン キャンサー インスティチュート 体液中癌細胞の検出
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
KR20070085275A (ko) * 2004-09-20 2007-08-27 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 멀티플 모드에 의한 멀티플렉스 반응 억제 방법
EP2287303B1 (de) 2004-11-12 2014-07-02 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
EP1863908B1 (de) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
US8197420B2 (en) 2006-12-18 2012-06-12 Magnolia Medical Technologies, Inc. Systems and methods for parenterally procuring bodily-fluid samples with reduced contamination
EP2134677B1 (de) 2006-12-20 2011-10-12 Bayer HealthCare LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en) * 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2198050A1 (de) * 2007-09-14 2010-06-23 Asuragen, INC. Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
EP2271757A2 (de) * 2008-03-26 2011-01-12 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit mir-16 und prostatakrebstherapie
US20090258928A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
AU2009260022A1 (en) * 2008-06-19 2009-12-23 John Wayne Cancer Institute Use of RUNX3 and miR-532-5p as cancer markers and therapeutic targets
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
EP2446271A1 (de) * 2009-06-26 2012-05-02 Erasmus University Medical Center Rotterdam Identifizierung von zirkulierenden tumorzellen (ctcs) mit cd146 bei brustkrebspatienten
WO2012040168A2 (en) * 2010-09-20 2012-03-29 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US8535241B2 (en) 2011-10-13 2013-09-17 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US8864684B2 (en) 2011-10-13 2014-10-21 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2013064699A1 (en) * 2011-11-04 2013-05-10 Royal College Of Surgeons In Ireland Adam22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
US9060724B2 (en) 2012-05-30 2015-06-23 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9022951B2 (en) 2012-05-30 2015-05-05 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2014022275A1 (en) 2012-08-01 2014-02-06 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2014058945A1 (en) 2012-10-11 2014-04-17 Bullington Gregory J Systems and methods for delivering a fluid to a patient with reduced contamination
RU2537263C2 (ru) * 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)
WO2014066179A1 (en) * 2012-10-24 2014-05-01 Clontech Laboratories, Inc. Template switch-based methods for producing a product nucleic acid
EP2925228B1 (de) 2012-11-30 2018-09-26 Magnolia Medical Technologies, Inc. Flüssigkeitsumleitungsmechanismus für eine spritze zur körperflüssigkeitsprobenahme
CN107874786B (zh) 2012-12-04 2020-11-24 木兰医药技术股份有限公司 用于从患者获取体液样本的设备
US10772548B2 (en) 2012-12-04 2020-09-15 Magnolia Medical Technologies, Inc. Sterile bodily-fluid collection device and methods
EP2967462B8 (de) 2013-03-12 2018-11-14 Magnolia Medical Technologies, Inc. Verfahren und vorrichtung zum selektiven verschliessen des lumens einer nadel
EP4218708A3 (de) 2014-03-03 2023-08-16 Magnolia Medical Technologies, Inc. Vorrichtung und verfahren zur desinfektion eines probenbehälters
US11234626B2 (en) 2015-06-12 2022-02-01 Magnolia Medical Technologies, Inc. Devices and methods for syringe-based fluid transfer for bodily-fluid sampling
EP4249119A3 (de) 2015-09-03 2023-11-29 Magnolia Medical Technologies, Inc. System zum aufrechterhalten der sterilität eines probenbehälters
US11076787B2 (en) 2017-09-12 2021-08-03 Magnolia Medical Technologies, Inc. Fluid control devices and methods of using the same
CN110628905A (zh) * 2018-06-25 2019-12-31 武汉菲思特生物科技有限公司 一种用于乳腺原位癌的诊断标志物检测试剂盒及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009456A1 (de) * 1989-02-16 1990-08-23 Viktor Balazs Malignitätstest (krebs-test) mit verwendung von der polymerasekettenreaktion
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden

Also Published As

Publication number Publication date
AU5310296A (en) 1996-10-08
EP1505159B1 (de) 2008-05-28
EP0871768A1 (de) 1998-10-21
ATE270712T1 (de) 2004-07-15
EP1505159A1 (de) 2005-02-09
DE69637552D1 (de) 2008-07-10
DE69632870T2 (de) 2005-07-14
ATE397097T1 (de) 2008-06-15
US6057105A (en) 2000-05-02
EP0871768B1 (de) 2004-07-07
WO1996029430A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
DE69632870D1 (de) Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
ATE130873T1 (de) Nachweis der expression von neu genen und produkten.
DE50011820D1 (de) Verfahren zur kultivierung von krebszellen aus humangewebe und vorrichtung zur aufbereitung von gewebeproben
DE3750198D1 (de) Hybridisierungssonden.
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
ATE433498T1 (de) Detektion von neoplasien durch speichelanalyse
ATE392180T1 (de) Identifikation duktaler öffnungen mittels charakteristischem elektrischen signal
ES2047033T3 (es) Un metodo para preparar compuestos de hidroxivitamina d.
DE69734236D1 (de) Genetische marker und methoden zum detektion von escherichia coli serotype-0157:h7
WO1994012881A3 (en) A method for detecting growing cells using translationally controlled tumor protein p21
DE68926658D1 (de) Diagnostische gene zum nachweis von toxoplasmose
ATE105569T1 (de) Antigene, antikoerper und verfahren zur identifizierung humaner metastatischer tumoren und zellinien zur herstellung dieser antikoerper.
ATE309389T1 (de) Verfahren zum entdecken von telomerase-aktivität
ATE224453T1 (de) Verwendung eines spezifischen markers zur detektion von salmonellen mit pcr
ES2054880T3 (es) Metodo de detectar tumores que contengan un defecto genetico del retinoblastoma.
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
ATE11930T1 (de) In vitro verfahren zum bestimmen von krebs im saeugergewebe.
EP0206065A3 (de) Verfahren zum Nachweis von oncogenischen und proto-oncogenischen Proteinen in extrazelligen biologischen Flüssigkeiten
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
WO2000061814A8 (en) Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
DE68925457D1 (de) Diagnoseverfahren für infektionskrankheiten sowie verfahren zum nachweis und identifizierung von mikroorganismen
DK0950062T3 (da) Proteinmarkörer for esophageal cancer
Khepar TECHNIQUES FOR GROUNDWATER INVESTIGATION IN DRAINAGE SURVEYS IN THE PUNJAB
ES408050A3 (es) Procedimiento de obtencion de salinomicina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition